Business Context and Reporting Period
This Form 8-K Current Report was filed by Aerpio Pharmaceuticals, Inc. on April 4, 2019, regarding events occurring on April 1, 2019. The filing discloses a strategic realignment plan approved by the Board of Directors to reduce operating costs and align the workforce with ongoing business needs. Note: The request metadata references "Whitehawk Therapeutics, Inc.," but the source document explicitly identifies the registrant as Aerpio Pharmaceuticals, Inc.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the exit costs associated with the realignment plan:
- Estimated One-Time Expenses: Approximately $0.9 million.
- Expense Components: Employee-related costs including severance benefits, healthcare insurance premiums, and outplacement assistance.
- Payment Timeline: Majority of costs expected to be paid in Q2 and Q3 2019, with remaining costs paid through the end of fiscal year 2019.
Material Changes
The primary material change is a significant reduction in the Company's workforce:
- Workforce Reduction: 11 employees eliminated.
- Impact: Represents approximately 41% of the total workforce.
- Completion Date: The action is expected to be substantially complete by April 30, 2019.
Outlook, Risks, and Contingencies
Management commentary indicates that the estimated charges are subject to various assumptions, and actual results may differ from the original estimate. The Company notes the following risks and contingencies:
- Additional Costs: The Company may incur additional costs not currently contemplated due to events associated with the realignment plan.
- Disclosure Obligation: If significant additional costs are determined, the Company will amend this Current Report to disclose such information.
- Contingency for Benefits: Eligibility for severance benefits is contingent upon the execution of a separation agreement including a general release of claims.
Investor Verification Checklist
- Verify the exact number of employees remaining post-reduction to confirm the 41% reduction figure.
- Monitor future filings for any amendments regarding additional costs exceeding the $0.9 million estimate.
- Review the Company's cash position to ensure liquidity is sufficient to cover the $0.9 million in severance and related costs during Q2 and Q3 2019.
- Confirm the status of separation agreements with affected employees to validate the accrual of liabilities.